Cell Biotech CO

At a glance

Cell Biotech CO filed 19 disclosures in the last 12 months, including 3 earnings and 2 insider. The most recent key filing was on Aug 7.

Revenue for 2025 was ₩53.1B, up 6.4% on 2024. Operating margin was 14.9% against 13.6% a year earlier. Debt was 4% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩30.4B and operating profit of ₩4.8B.

The 2025 annual report lists 123 employees with an average tenure of 6.8 years and average pay of ₩45.9M, #1621 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩138M each on average. It paid ₩600 per common share in cash dividends, against ₩450 a year earlier (+33.3%). 정명준 and related parties held 25.71% at year end.

From the 2025 annual report

Staff: 123 (87 men, 36 women), of whom 18 on fixed-term contracts. Total pay for the year: ₩5.6B. Directors and auditors: 9, paid ₩1.2B in total.

Dividends (common shares)

Largest shareholder

정명준 holds 18.49%; with 6 related parties the group holds 25.71% of common shares at year end (from 25.15% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary